| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive VP, CFO & COO
1 company
Donald Marvin last filed a Form 4 in March 2022, as Executive VP, CFO & COO at CMMB. Donald Marvin's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 2,000 shares of CMMB. Net of sales, the CMMB filings show accumulation of 1,750 shares.
Donald Marvin has 2 Form 4 filings on record in March 2022, all as Executive VP, CFO & COO at Chemomab Therapeutics (CMMB), 2022.
The 9 reported transactions were 7 open-market purchases and 2 option or other derivative awards.
Counted by filing, the open-market trades come to 2 purchases worth about $7K and no sales.
The largest open-market purchase was 1,250 shares of CMMB at an average $4.04 on March 14, 2022, about $5K. Twelve months later CMMB was down 62%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.